Investors

As of 30 September 2021

£1.2bn

Net assets

172p

NAV per share

(11.4)%

NAV per share growth over previous 6 months

£618m

Value of life science portfolio

(21.3)%

Return from life science portfolio over previous 6 months

£535m

Capital pool

Regulatory News

Syncona appoints new Directors

Achilles Presents Data at the SITC Annual Meeting

Half-year Report

Freeline reports new data and 3rd Quarter Results

Achilles reports Third Quarter Financial Results

Gyroscope Announces Sanofi Equity Investment

Blackstone Life Science to invest $250m in Autolus

Syncona leads $87 million financing of Clade

Autolus reports Q3 2021 Financial Results

Notice of Results

Gyroscope announces additional positive data

First Quarter Update

Freeline Reports Executive Change and Q2 Results

Achilles reports Second Quarter 2021 Results

Autolus reports Q2 2021 Financial Results

Result of AGM - Replacement

Result of AGM

Total Voting Rights

View all

Search